You're not right in one sense Whytee but I'm sure if you were given the opportunity to purchase a good number of shares in any company @27c and could sell them at somewhere near a $1 straight away you'd consider selling some to cover the base cost. In my experience there is no such thing as a sure thing in biotech but with respect to Opthea I see a well run company with a science that appears very logical and this makes me quietly confident but, and there's always the potential for "buts" in biotech.
Ann: Appendix 3B, page-4
Add OPT (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
38.0¢ |
Change
0.000(0.00%) |
Mkt cap ! $467.8M | |||
| Open | High | Low | Value | Volume |
| 38.0¢ | 39.0¢ | 37.5¢ | $176.6K | 463.9K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 7 | 121324 | 38.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 39.0¢ | 90033 | 3 |
View Market Depth
| Last trade - 16.10pm 19/07/2024 (20 minute delay) ? |
| OPT (ASX) Chart |